External broker reports(aggregated public sources), Topline Securities

Topline Securities

Topline Securities is one of the fastest growing brokerage houses in Pakistan. It has strong equity brokerage, economic / equity research, mutual fund distribution, commodity trading and corporate finance & advisory functions. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Citi Pharma (CPHL) announced its 1QFY25 result today, where the company recorded earnings of Rs201mn (EPS of Rs0.88), up 114% YoY and 32% QoQ.</li><li>The result came higher than expectations due to higher than expected net sales.</li><li>CPHL's net sales increased by 19% YoY and 12% QoQ to Rs3.2bn in 1QFY25. This improvement is primarily due to an increase in API volumetric sales and the addition of new formulation products, as per our channel checks.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Citi Pharma (CPHL) announced its 1QFY25 result today, where the company recorded earnings of Rs201mn (EPS of Rs0.88), up 114% YoY and 32% QoQ.The result came higher than expectations due to higher than expected net sales.CPHL's net sales increased by 19% YoY and 12% QoQ to Rs3.2bn in 1QFY25. This improvement is primarily due to an increase in API volumetric sales and the addition of new formulation products, as per our channel checks.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Citi Pharma (CPHL): 1QFY25 EPS at Rs0.88 up 32% QoQ  (Earnings higher than expectations)

Citi Pharma Limited

Citi Pharma (CPHL): 1QFY25 EPS at Rs0.88 up 32% QoQ (Earnings higher than expectations)